People with immunocompromising conditions and a range of other underlying conditions will be prioritised in the COVID-19 vaccine phase 1B.
Immunocompromising conditions include:
Solid organ transplant recipients who are on immune suppressive therapy;
Adult survivors of childhood cancers;
Bone marrow transplant recipients, or those on chimeric antigen receptor T-cell (CAR-T) therapy, or those on immune suppressive therapy for graft versus host disease;
Haematological diseases or cancers including leukaemia, lymphoma or myeloma diagnosed within the past five years or on recently completed active treatment including chemotherapy, radiotherapy, immunotherapy or targeted anti-cancer therapy or with advanced disease regardless of treatment;
Non-haematological cancer diagnosed within the past five years or on recently completed active treatment including chemotherapy, radiotherapy, immunotherapy or targeted anti-cancer therapy or with advanced disease regardless of treatment;
Chronic inflammatory conditions on medical treatments including Systemic Lupus Erythematosus, Rheumatoid Arthritis, Crohn’s disease, ulcerative colitis, and similar who are being treated with disease modifying anti-rheumatic drugs (DMARDs) or immune-suppressive or immunomodulatory therapies. Generally not inclusive of people living with osteoarthritis, fibromyalgia, myalgic encephalomyelitis/chronic fatigue syndrome or similar non-immunocompromising inflammatory conditions;
Primary or acquired immunodeficiency including congenital causes of immunodeficiency and HIV/AIDS;
Those with severe mental health conditions including schizophrenia and bi-polar disorder.
Other underlying conditions include:
Chronic renal (kidney) failure with an eGFR of <44mL/min;
Does not include mild-moderate chronic kidney disease;
Heart disease including Ischaemic heart disease, valvular heart disease, cardiomyopathies and pulmonary hypertension;
Chronic lung disease including Chronic Obstructive Pulmonary Disease, cystic fibrosis, interstitial lung disease;
Does not include mild or moderate asthma;
Severe obesity with a BMI ≥ 40kg/m2;
Chronic liver disease;
Some neurological conditions including Stroke, dementia, Multiple sclerosis, motor neurone disease, Parkinson’s disease, cerebral palsy;
Generally not inclusive of migraine or cluster headaches;
Poorly controlled blood pressure defined as two or more pharmacologic agents for blood pressure control, regardless of recent readings;
Those with Down syndrome, muscular dystrophy, traumatic brain and spinal cord injury.